LEQEMBI® in Early Alzheimer’s Disease (AD): MCI Due to AD or Mild AD Dementia
Date: September 14, 2025
Time: 3:30 pm to 5:00 pm
Room: Dover A - C (Third Floor Level)
Track: Satellite Symposia
Session Description
Join our esteemed experts, Dr. Schreiber and Dr. Moon, as they explore our understanding of Alzheimer’s disease pathophysiology and the current treatment landscape. Through an interactive patient case study, our speakers will provide expert guidance on the LEQEMBI patient journey, including patient selection, diagnosis, treatment, and management. This will be supported by key efficacy and safety findings from the Phase 3 Clarity AD clinical study, including long-term data from the open-label extension, to help inform treatment and management decisions. The speakers will provide recommendations for implementation of an integrated LEQEMBI treatment service line, including the role of a multi-disciplinary team and best practices. At the end of the symposium, there will be an opportunity to engage directly with our speakers during the Q+A session.
Faculty
Facilitator: Justin Moon, MD, MPH
Speaker: Curtis Schreiber, MD
Provided By: Eisai, Inc., an ANA2025 Gold Sponsor
Learning Objectives
- Mechanism of disease: To understand the underlying pathological mechanisms of AD
- Patient identification: To understand how to identify the appropriate patient for LEQEMBI
- LEQEMBI efficacy and safety: To understand the key clinical efficacy and safety data for LEQEMBI, including all information on potential side effects to help inform treatment and management decisions
- Patient pathway: To understand how to navigate the steps from diagnosis to treatment with LEQEMBI, including recommendations for implementation of a LEQEMBI treatment service line
Disclaimer
This session is not sponsored or programmed by the American Neurological Association (ANA). The faculty are presenting on behalf of, and are paid consultants for Eisai, Inc.
The ANA values the participation of our corporate partners and is supportive of the role that members of this community continue to play in our efforts to provide neurologists & neuroscientists with quality educational programs. These symposia are not part of the ANA official educational program, and the sessions and content are not endorsed by ANA.
The ANA does not provide continuing medical education (CME) credits for Satellite Symposia and assumes no responsibility for credits offered by other organizations. Accredited providers are solely responsible for the content, quality, and scientific integrity of their Satellite Symposia.